Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.

Ann R FalseyTessa HosmanArangassery Rosemary BastianSjouke VandenbergheEric K H ChanMacaya DouoguihEsther HeijnenChristy A ComeauxBenoit Callendretnull null

Published in: The Lancet. Infectious diseases (2024)

Janssen Vaccines & Prevention.

Keyphrases

placebo controlled
double blind
clinical trial
phase iii
study protocol
respiratory syncytial virus
phase ii
phase ii study
respiratory tract
open label
protein protein
squamous cell carcinoma
randomized controlled trial